Syntara expands scar trial cohort to 30 participants
- Syntara expanded its Phase 1b clinical study cohort for hypertrophic sternotomy scars from 20 to 30 participants.
- Following the announcement, the Syntara share price was unchanged at $0.022.
- The company stated that expanding the trial provides a larger safety and tolerability dataset while maintaining a blinded study design.
Syntara (ASX:SNT) has expanded its double-blind, placebo-controlled Phase 1b clinical study of its topical drug SNT-9465 from 20 to 30 participants following encouraging feedback from clinical sites.
The expansion comes as recruitment for the initial 20-participant cohort approaches completion, building on earlier Phase 1a results that confirmed dose-dependent inhibition.
The study is designed to assess the safety and tolerability of topical SNT-9465, alongside exploratory measures of biological and clinical activity in hypertrophic scars following sternotomy surgery.
To support timely recruitment for the expanded cohort, the company added The Skin Hospital in Sydney as an additional clinical site and updated its timeline, with top-line study results now expected in Q1 2027.
Following the announcement, the Syntara share price was unchanged at $0.022.
Syntara operates as a clinical-stage drug development company focused on advancing novel treatments for skin scarring, inflammation, and fibrotic diseases.
The company is also conducting an exploratory trial for SNT-6302 in keloid scarring, where six participants recently completed a 12-week treatment period.
